MPG.eBooks - Staff View: CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris -- Alexion Pharma Canada Corp.)

Read Now

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, October 2020
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK567285
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa


LEADER	01013nam a2200229 u 4500
001	EB002010802
003	EBX01000000000000001173701
005	00000000000000.0
007	tu\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
008	220201 r \|\|\| eng
245	0	0	\|a CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris -- Alexion Pharma Canada Corp.) \|h Elektronische Ressource \|b indication : adult patients with refractory generalized myasthenia gravis
246	3	1	\|a Eculizumab (Soliris -- Alexion Pharma Canada Corp.)
260			\|a Ottawa (ON) \|b Canadian Agency for Drugs and Technologies in Health \|c 2020, October 2020
300			\|a 1 PDF file (9 pages)
710	2		\|a CADTH Canadian Drug Expert Committee
710	2		\|a Canadian Agency for Drugs and Technologies in Health
041	0	7	\|a eng \|2 ISO 639-2
989			\|b NCBI \|a National Center for Biotechnology Information
490	0		\|a CADTH common drug review
500			\|a "Final."
856	4	0	\|u https://www.ncbi.nlm.nih.gov/books/NBK567285 \|3 Volltext
082	0		\|a 140